Adaptive Biotechnologies stock hits 52-week high at 26.89 USD
What it means
- What to watch: Approvals and strong trial data can reprice a drugmaker quickly — especially when one product is most of the company.
- How the stock is trading: $ADPT +4.29% in the latest session.
- Timing: It dropped mid-session, while New York was open, so the move beside it may already include the market's first reaction.
Where the stock stands
$ADPT last changed hands at $27.98, +4.29% on the session, 9.0% below its 52-week high of $30.74 and 133% above its low of $12.00 — in the upper part of the range. Over the year it has ranged 156% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $ADPT page.
How much coverage it is getting
Wook has logged 2 stories on $ADPT in the last 30 days, 1 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal; the press has found a reason to keep writing. Across those stories 0 read bullish, 2 neutral and 0 bearish — mostly headline writers keeping a straight face. This one reads bullish, so it sits in a small minority — the contrarian in the room. 2 of the 2 (100%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
What to watch next
For the receipts, the $ADPT page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ADPT is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. It reads bullish at medium severity because of “high” in the wording, with nothing on the bearish side to offset it. It was matched to $ADPT. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 15, 2026. $ADPT has moved +1.12% ($27.67 to $27.98). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.